Patents Assigned to International Stem Cell Corporation
-
Patent number: 11324778Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.Type: GrantFiled: November 18, 2015Date of Patent: May 10, 2022Assignee: International Stem Cell CorporationInventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
-
Patent number: 11007232Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.Type: GrantFiled: August 6, 2018Date of Patent: May 18, 2021Assignee: International Stem Cell CorporationInventors: Russell A. Kern, Rodolfo Gonzalez, Ibon Garitaonandia
-
Patent number: 10457915Abstract: The present invention is based in part on a chemically defined method of generating retinal epithelial cells and retinal pigmented epithelial cells from human pluripotent stem cells (hpSCs). The present invention also provides methods and kits for treating degenerative eye disorders.Type: GrantFiled: May 14, 2015Date of Patent: October 29, 2019Assignee: International Stem Cell CorporationInventors: Russell A. Kern, Rodolfo Gonzalez
-
Patent number: 10335422Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.Type: GrantFiled: June 27, 2016Date of Patent: July 2, 2019Assignee: International Stem Cell CorporationInventors: Rodolfo Gonzalez, Maxim Poustovoitov, Russell A. Kern
-
Patent number: 10258632Abstract: Provided herein are small molecules that have a neuroprotective or modulatory effect in the nervous system. The small molecules provided herein modulate dopaminergic neuronal activity. Also provided herein are methods of for the prophylaxis of or preventing the progression of Parkinson's Disease (PD).Type: GrantFiled: June 3, 2013Date of Patent: April 16, 2019Assignee: International Stem Cell CorporationInventors: Rodolfo Gonzalez, Ibon Garitaonandia, Russell A. Kern
-
Patent number: 10039794Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.Type: GrantFiled: February 14, 2014Date of Patent: August 7, 2018Assignee: International Stem Cell CorporationInventors: Russell A. Kern, Rodolfo Gonzalez, Ibon Garitaonandia
-
Patent number: 9926529Abstract: The present invention is based in part on a chemically defined method of generating neural stem cells (NSCs) and dopaminergic (DA) neurons from human pluripotent stem cells (hPSCs). The DA neurons of the invention can be derived from hPSCs and NSCs. The present invention also provides reagents and kits useful for the derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells.Type: GrantFiled: April 23, 2013Date of Patent: March 27, 2018Assignee: International Stem Cell CorporationInventors: Rodolfo Gonzalez, Ibon Garitaonandia, Ruslan Semechkin
-
Patent number: 9920299Abstract: Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.Type: GrantFiled: November 24, 2015Date of Patent: March 20, 2018Assignee: International Stem Cell CorporationInventors: Elena S. Revazova, Leonid N. Kuzmichev, Nickolay A. Turovets, Jeffrey D. Janus
-
Patent number: 9375439Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.Type: GrantFiled: January 8, 2014Date of Patent: June 28, 2016Assignee: International Stem Cell CorporationInventors: Rodolfo Gonzalez, Maxim Poustovoitov, Ruslan Semechkin
-
Patent number: 8986995Abstract: The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells.Type: GrantFiled: September 14, 2012Date of Patent: March 24, 2015Assignee: International Stem Cell CorporationInventors: Nikolay Turovets, Larisa Agapova, Andrey Semechkin, Jeffrey Janus
-
Patent number: 8945083Abstract: A light sensitive media packaging with unique shrink-wrap light protection label that works as a light barrier to protect media from light damage.Type: GrantFiled: April 12, 2011Date of Patent: February 3, 2015Assignee: International Stem Cell CorporationInventor: Jeffrey Janus
-
Publication number: 20140314721Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.Type: ApplicationFiled: February 14, 2014Publication date: October 23, 2014Applicant: INTERNATIONAL STEM CELL CORPORATIONInventors: Ruslan Semechkin, Rudolfo Gonzalez, Ibon Garitaonandia
-
Publication number: 20140309195Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.Type: ApplicationFiled: January 8, 2014Publication date: October 16, 2014Applicant: INTERNATIONAL STEM CELL CORPORATIONInventors: Rodolfo Gonzalez, Maxim Poustovoitov, Ruslan Semechkin
-
Patent number: 8420393Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.Type: GrantFiled: January 17, 2012Date of Patent: April 16, 2013Assignee: International Stem Cell CorporationInventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
-
Patent number: 8268621Abstract: The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells.Type: GrantFiled: December 2, 2009Date of Patent: September 18, 2012Assignee: International Stem Cell CorporationInventors: Nikolay Turovets, Larisa Agapova, Andrey Semechkin, Jeffrey Janus
-
Publication number: 20120100110Abstract: The disclosure provides methods for isolating a pure or enriched population of differentiated cells derived from stem cells, comprising differentiating the population of stem cells; and migrating the differentiated cells through a porous membrane in a differentiation device to isolate the pure or enriched population of differentiated cells. The disclosure also provides a differentiation device for isolating a pure or enriched population of differentiated cells derived from stem cells, the device comprising a porous membrane; and an extracellular matrix.Type: ApplicationFiled: April 19, 2011Publication date: April 26, 2012Applicant: INTERNATIONAL STEM CELL CORPORATIONInventors: Nikolay Turovets, Andrey Semechkin, Larissa Agapova, Jeffrey Janus
-
Publication number: 20120070419Abstract: The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS) cells, as well as differentiate, transdifferentiate or dedifferentiate cells of various epigenetic status. The method includes introduction of a nucleic acid construct, or expression product thereof, into a cell, and culture of the cell under culture conditions that efficiently converts the cell into a pluripotent cell, enhances the retention of the pluripotent state or efficiently converts the cell into a cell of a cell lineage corresponding to endoderm, mesoderm or ectoderm.Type: ApplicationFiled: March 21, 2011Publication date: March 22, 2012Applicant: INTERNATIONAL STEM CELL CORPORATIONInventor: Trudy Christiansen-Weber
-
Patent number: 7935100Abstract: A light sensitive media packaging with unique shrink-wrap light protection label that works as a light barrier to protect media from light damage.Type: GrantFiled: December 5, 2006Date of Patent: May 3, 2011Assignee: International Stem Cell CorporationInventor: Jeffrey Janus
-
Publication number: 20100173414Abstract: The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells.Type: ApplicationFiled: December 2, 2009Publication date: July 8, 2010Applicant: INTERNATIONAL STEM CELL CORPORATIONInventors: Nikolay Turovets, Larisa Agapova, Andrey Semechkin, Jeffrey Janus
-
Patent number: 7732202Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.Type: GrantFiled: August 15, 2006Date of Patent: June 8, 2010Assignee: International Stem Cell CorporationInventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus